This year, the Rowan team has worked with scientists and engineers from Peapack, N.J., and the Kalamazoo, Mich., plant where drugs such as the widely prescribed SOLU-MEDROL® are made along with other highly specialized medicines.
The Rowan team has been working with several Pfizer personnel, including Frank J. Urbanski (director, Pfizer Global Engineering), Joseph W. Geiger (manager API engineering), and Donald J. Knoechel (senior principal scientist).
The team has collaborated to analyze the economic viability and to quantify the environmental benefits of investing in a small solvent recovery system, as an alternative to incineration, for addressing smaller-volume waste streams. Solvents often represent the primary component of waste from the production of active pharmaceutical ingredients (APIs), used in medicinal formulations.
According to Urbanski, “There are economic and environmental benefits when Pfizer recovers solvent for re-use, especially when expensive solvents and large volumes are involved. Indeed, Pfizer has been recovering solvents for many decades at its various manufacturing facilities. As we seek to improve our conservation efforts and reduce our carbon footprint, one challenge faced is how best to deal with numerous small-volume waste streams from multi-product facilities, when existing solvent recovery equipment may be too large to be practical.”
Solvent recovery is a routine practice in the pharmaceutical industry when it is technically and economically viable for the particular waste stream. Capital investment in the required piping, tank farms and recovery equipment is more easily justified when dealing with large volumes, high-cost solvents and high equipment-utilization rates and when solvents from multiple products can be pooled together – i.e., they don’t require segregation by product. The use of recovered solvents, and the pooling of solvents, must be appropriately qualified to assure product quality and avoid cross contamination. Economic justification to recover small-volume, “non-poolable,” and intermittently generated waste streams remains challenging but a potential recovery opportunity.
Drs. Mariano J. Savelski and C. Stewart Slater, both Rowan chemical engineering professors, are leading this research effort with a team of chemical engineering students: Joseph Hankins (Blairstown, N.J.), Christopher Mazurek (Jackson, N.J.), James Peterson (Jackson, N.J.), Michael Raymond (Burlington Township, N.J.), and Andrew Tomaino (Middleton, N.J.).
The Rowan team performed a case study on several waste streams being generated at an API synthesis building at the Pfizer Kalamazoo plant. The goal was to investigate those streams that could be most easily recovered with traditional separation and purification processes. As a first step in that analysis, the recovery of acetonitrile solvent from a waste stream in the selamectin synthesis was considered. Selamectin is the active ingredient in the veterinary drug REVOLUTION®. This stream was initially chosen due to the relative high cost (and value) of acetonitrile and the ability to separate acetonitrile from acetone.
Rowan designed a small-scale distillation, solvent-recovery system, and the proposed operation compared with the current waste-disposal practice. To increase the economic feasibility of a potential capital investment and improve the environmental footprint further, the Rowan team evaluated the proposed design for use with the other waste streams in the facility. The simulation included isopropanol solvent recovery from the manufacture of nelfinavir, the active ingredient in the antiretroviral drug VIRACEPT®, used in the treatment of the human immunodeficiency virus (HIV). The study also examined toluene recovery from hydrocortisone manufacture (used in several drug products for relief of inflammation).
“The case study estimates the environmental impacts and economics, using life-cycle assessment, associated with the proposed improvement using various computer routines,” Savelski said.
Knoechel said, “From a plant perspective, the Rowan team has given us some valuable estimates to use in evaluating our solvent use and disposal practices. The team’s unique life-cycle assessment capability helps us understand where we can have the most impact on reducing our greenhouse gas emissions.”
The case study for the three drugs showed that 732,000 kg/yr of life cycle emissions, of which 677,000 kg/yr are CO2, could be reduced through using the solvent recovery system. This results from not having to manufacture the virgin solvent as well as from a reduction in waste disposal. The study also projects significant operating cost benefit. The CO2 reductions are equivalent to the amount of emissions saved by not driving cars 1.4 million miles in a year.
The Rowan group presented its work at the 14th Green Chemistry and Engineering Conference in Washington, D.C., in June.
Both Pfizer and Rowan recently have been recognized for their green chemistry and engineering achievements. Pfizer’s La Jolla (Calif.) research and development facility won a Clean Air Champions award from the County of San Diego in 2009. Rowan’s Savelski and Slater won the EPA’s Environmental Quality Award in 2009 for their efforts in educating both academia and industry in the field of green engineering. Rowan University’s prior work with Pfizer resulted in recommendations to improve the solvent-recovery operations in the manufacture of celecoxib, the active ingredient in the arthritis pain medication CELEBREX®.
Pfizer and Rowan continue to discuss further green engineering partnerships.
*Celebrex®, Revolution®, Solu-Medrol® and Viracept® are registered trademarks of Pfizer Inc. and its affiliated companies
Patricia Quigley | Newswise Science News
Researchers identify potentially druggable mutant p53 proteins that promote cancer growth
09.12.2016 | Cold Spring Harbor Laboratory
Plant-based substance boosts eyelash growth
09.12.2016 | Fraunhofer-Institut für Angewandte Polymerforschung IAP
Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.
Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
09.12.2016 | Life Sciences
09.12.2016 | Ecology, The Environment and Conservation
09.12.2016 | Health and Medicine